fda compounding semaglutide news october 2025 Concerns Surrounding Compounded GLP-1s Mount As Shortages of Tirzepatide, End FDA Ban on Compounded GLP-1

It selectively promotes insulin secretion by pancreatic -cells and inhibits glucagon secretion by pancreatic -cells under hyperglycemic conditions, steadily regulating fasting and postprandial blood glucose

Most prior incretin-family peptides act on one or two of these receptors: Semaglutide (single agonist): GLP-1 receptor only Tirzepatide (dual agonist): GLP-1 + GIP receptors Retatrutide / GLP-3RT (triple agonist): GLP-1 + GIP + glucagon receptors That third receptor glucagon is the key reason researchers describe GLP-3RT as a next-generation tool in incretin pharmacology research

Recalculate units for the split dose amount using the same concentration formula

These often occur within a week of starting semaglutide, though noticeable changes in weight or blood sugar take longer